Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.merus.nl
Merus News Releases
Get the latest updates from Merus News Releases directly as they happen.
Follow now 56 followers
Latest posts
Last updated 2 days ago
Merus to Present at BofA Securities 2025 Health Care Conference
2 days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 08, 2025 (GLOBE NEWSWIRE)...
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
3 days ago
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase...
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
17 days ago
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim...
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
about 1 month ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 01, 2025 (GLOBE NEWSWIRE)...
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
2 months ago
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in...
Merus to Present at Upcoming Investor Conferences
2 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 25, 2025 (GLOBE NEWSWIRE)...
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
3 months ago
This marks the second BTD for petosemtamab in HNSCC UTRECHT, The Netherlands...
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
3 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 13, 2025 (GLOBE NEWSWIRE)...
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
3 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 05, 2025 (GLOBE NEWSWIRE)...
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
4 months ago
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Jan...
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
5 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Dec. 16, 2024 (GLOBE NEWSWIRE)...
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
5 months ago
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing...